View in EDS

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Authors: Madruga, José Valdez, Berger, Daniel, McMurchie, Marilyn, Suter, Fredy, Banhegyi, Denes, Ruxrungtham, Kiat, Norris, Dorece, Lefebvre, Eric, de Béthune, Marie-Pierre, Tomaka, Frank, De Pauw, Martine, Vangeneugden, Tony, Spinosa-Guzman, Sabrina
Source: Lancet. 7/7/2007, Vol. 370 Issue 9581, p49-58. 10p. 4 Charts, 4 Graphs.
Subjects: Clinical trial registries, HIV infections, Therapeutics, HIV-positive persons, Protease inhibitors, Clinical drug trials, Health outcome assessment
Abstract: This article reports on a clinical trial studying the efficacy and safety of darunavir-ritonavir compared with lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial. The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced HIV patients. This study looks at the comparison of darunavir with lopinavir in treatment-experienced lopinavir-naive patients. The study found that in treatment-experienced patients, darunavir was non-inferior to lopinavir treatment in terms of the virological endpoint and can therefore be considered as a treatment for this population.
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 25691945
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Madruga%2C+José+Valdez%22">Madruga, José Valdez</searchLink><br /><searchLink fieldCode="AR" term="%22Berger%2C+Daniel%22">Berger, Daniel</searchLink><br /><searchLink fieldCode="AR" term="%22McMurchie%2C+Marilyn%22">McMurchie, Marilyn</searchLink><br /><searchLink fieldCode="AR" term="%22Suter%2C+Fredy%22">Suter, Fredy</searchLink><br /><searchLink fieldCode="AR" term="%22Banhegyi%2C+Denes%22">Banhegyi, Denes</searchLink><br /><searchLink fieldCode="AR" term="%22Ruxrungtham%2C+Kiat%22">Ruxrungtham, Kiat</searchLink><br /><searchLink fieldCode="AR" term="%22Norris%2C+Dorece%22">Norris, Dorece</searchLink><br /><searchLink fieldCode="AR" term="%22Lefebvre%2C+Eric%22">Lefebvre, Eric</searchLink><br /><searchLink fieldCode="AR" term="%22de+Béthune%2C+Marie-Pierre%22">de Béthune, Marie-Pierre</searchLink><br /><searchLink fieldCode="AR" term="%22Tomaka%2C+Frank%22">Tomaka, Frank</searchLink><br /><searchLink fieldCode="AR" term="%22De+Pauw%2C+Martine%22">De Pauw, Martine</searchLink><br /><searchLink fieldCode="AR" term="%22Vangeneugden%2C+Tony%22">Vangeneugden, Tony</searchLink><br /><searchLink fieldCode="AR" term="%22Spinosa-Guzman%2C+Sabrina%22">Spinosa-Guzman, Sabrina</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 7/7/2007, Vol. 370 Issue 9581, p49-58. 10p. 4 Charts, 4 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Clinical+trial+registries%22">Clinical trial registries</searchLink><br /><searchLink fieldCode="DE" term="%22HIV+infections%22">HIV infections</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22HIV-positive+persons%22">HIV-positive persons</searchLink><br /><searchLink fieldCode="DE" term="%22Protease+inhibitors%22">Protease inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+drug+trials%22">Clinical drug trials</searchLink><br /><searchLink fieldCode="DE" term="%22Health+outcome+assessment%22">Health outcome assessment</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: This article reports on a clinical trial studying the efficacy and safety of darunavir-ritonavir compared with lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial. The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced HIV patients. This study looks at the comparison of darunavir with lopinavir in treatment-experienced lopinavir-naive patients. The study found that in treatment-experienced patients, darunavir was non-inferior to lopinavir treatment in terms of the virological endpoint and can therefore be considered as a treatment for this population.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=25691945
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(07)61049-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 49
    Subjects:
      – SubjectFull: Clinical trial registries
        Type: general
      – SubjectFull: HIV infections
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: HIV-positive persons
        Type: general
      – SubjectFull: Protease inhibitors
        Type: general
      – SubjectFull: Clinical drug trials
        Type: general
      – SubjectFull: Health outcome assessment
        Type: general
    Titles:
      – TitleFull: Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Madruga, José Valdez
      – PersonEntity:
          Name:
            NameFull: Berger, Daniel
      – PersonEntity:
          Name:
            NameFull: McMurchie, Marilyn
      – PersonEntity:
          Name:
            NameFull: Suter, Fredy
      – PersonEntity:
          Name:
            NameFull: Banhegyi, Denes
      – PersonEntity:
          Name:
            NameFull: Ruxrungtham, Kiat
      – PersonEntity:
          Name:
            NameFull: Norris, Dorece
      – PersonEntity:
          Name:
            NameFull: Lefebvre, Eric
      – PersonEntity:
          Name:
            NameFull: de Béthune, Marie-Pierre
      – PersonEntity:
          Name:
            NameFull: Tomaka, Frank
      – PersonEntity:
          Name:
            NameFull: De Pauw, Martine
      – PersonEntity:
          Name:
            NameFull: Vangeneugden, Tony
      – PersonEntity:
          Name:
            NameFull: Spinosa-Guzman, Sabrina
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 07
              Text: 7/7/2007
              Type: published
              Y: 2007
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 370
            – Type: issue
              Value: 9581
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1